BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Conditions
- Relapsed/Refractory Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 780
- Registration Number
- NCT05100862
- Locations
- 🇩🇪
Universitaetsklinikum Ulm, Ulm, Germany
🇹🇷Ondokuz Mayis University Medicine Faculty Hospital, Atakum Samsun, Turkey
🇹🇷Dokuz Eylul University, Balcova, Turkey
First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT05093270
- Locations
- 🇦🇺
Q PHARM, Herston, Queensland, Australia
🇦🇺Nucleus Network, Melbourne, Victoria, Australia
🇨🇳The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao, Shandong, China
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
- Conditions
- Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 66
- Registration Number
- NCT05068440
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)Nonsmall Cell Lung Cancer, Stage IV
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 272
- Registration Number
- NCT05014815
- Locations
- 🇦🇺
Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
🇦🇹Universitätsklinikum Krems, Krems, Krems an der Donau, Austria
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 58
- Registration Number
- NCT05014828
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical Hospital, Hefei, Anhui, China
🇨🇳Beijing Luhe Hospital, Beijing, Beijing, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Conditions
- Marginal Zone LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaB-cell MalignancySmall Lymphocytic LymphomaFollicular LymphomaWaldenström MacroglobulinemiaNon-Hodgkin LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 621
- Registration Number
- NCT05006716
- Locations
- 🇫🇷
Hopital Estaing, Clermontferrand, France
🇫🇷Chu Henri Mondor, Creteil, France
🇫🇷Hopital Claude Huriez Chu Lille, Lille, France
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Conditions
- Resectable Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT04974047
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 167
- Registration Number
- NCT04973605
- Locations
- 🇺🇸
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
🇧🇷Hospital Sirio Libanes Brasilia, Brasilia, Brazil
🇧🇷Instituto Dor de Pesquisa E Ensino Distrito Federal, Brasilia, Brazil
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT04952597
- Locations
- 🇨🇳
Mianyang Central Hospital, Mianyang, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hwa Mei Hospital, University of Chinese Academy of Sciences, Zhejiang, China
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 94
- Registration Number
- NCT04948697
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China